Table 1 Relevant results of clinical examination, apparative diagnostics and laboratory results
From: Increase of nitrous oxide-induced neurological disorders – a German multicenter experience
Mean (SD) | Pathologic findings, n (%) | |
|---|---|---|
Clinical examination | ||
Paresthesia/Hypesthesia | 22/23 (95.7%) | |
Ataxia | 19/23 (82.6%) | |
Paresis | 12/23 (52.2%) | |
Hyporeflexia | 17/23 (73.9%) | |
Abnormal pallesthesia | 17/19 (88.5%) | |
Autonomic dysfunction | 3/23 (13.0%) | |
Other symptoms | 7/23 (30.0%) | |
Apparative Diagnostics | ||
MRI abnormalities | 15/21 (71.4%) | |
Myelopathy | 14/21 (66.7%) | |
Neuropathy | 20/20 (100%) | |
SSEP abnormal | 10/12 (83.3%) | |
Laboratory Results (reference range) | ||
Vitamin-B12 (200–1000 pg/ml) | 349.74 (209.53) | 8/23 (34.8%) |
Homocysteine (3.2–10.7 µmol/l) | 73.01 (43.51) | 8/9 (88.9%) |
Methylmalonic acid (< 32 ng/ml) | 475.38 (511.47) | 18/19 (94.7%) |
Holotranscobalamin (35–150 pmol/l) | 101.42 (36.88) | 5/15 (33.3%) |
Folate (4.5–32.2 ng/ml) | 9.23 (4.98) | 3/19 (21.1%) |
Hb (> 12 g/dl in females and > 13 g/dl in males) | 13.68 (1.64) | 6/23 (26.1%) |
MCV (80-100 fl.) | 92.68 (5.88) | 4/23 (17.4%) |
MCHC (31.5–36 g/dl) | 34.09 (1.00) | 0/23 (0%) |
CSF protein (150–650 g/l) | 0.41 (0.17) | 1/18 (5.6%) |
CSF cell count (≤ 5/µl) | 2.47 (1.76) | 1/19 (5.3%) |
CSF lactate (1.1–2.4 mmol/l) | 1.94 (0.40) | 2/17 (11.8%) |